Abstract Background: Dopamine level is strictly regulated at the synaptic level because a slight alteration can lead to severe neurological and neuropsychiatric consequences
1
. Dopamine transporter (DAT), which facilitates the reuptake of extracellular dopamine, used to be the sole component of regulating synaptic dopamine level. However, our previous discovery of a direct protein-protein interaction between DAT and presynaptic dopamine D2 receptor (D2R) revealed that this protein complex enables D2R to recruit extra intracellular DAT to the membrane surface and enhance dopamine reuptake 2 . Despite we uncovered this novel target for modulating dopaminergic tone, its effects at the behavioural level remain elusive. Methods: Male Sprague-Dawley rats were used in all three experiments. To examine the effects of D2R-DAT disruption on locomotion, normal rats and dopamine-depleted rats were injected intra-cranially (i.c.v.) with an interfering peptide to disrupt the interaction, and were subsequently placed in 43x43x30 cm open-field chambers to record their voluntary movements. Acute dopamine depletion was induced by two intra-peritoneal injections of α-methyl-p-tyrosine.
In vivo micro-dialysis was also performed in anesthetized rats, starting from the baseline and following after a single S1 injection (i.c.v.). The extracellular level of dopamine in the nucleus accumbens core was determined by high-performance liquid chromatography. Results: The disruption of D2R-DAT complex significantly elevated the voluntary movement in both normal animals and dopamine-depleted animals (p<0.05). The data collected from in vivo micro-dialysis indicated that the disruption of DAT-D2R interaction increased the extracellular dopamine level by approximately 30% compared to baseline. Discussion: The elevation in locomotion and increase in extracellular dopamine together prompted that the D2R-DAT interaction is another valid target site for modulating dopaminergic neurotransmission. More importantly, this study showed that this DAT-D2R protein complex can be a potential therapeutic target for disorders associated with dopamine dysregulation such as Parkinson's disease and attention deficit hyperactivity disorder 3 .
PT546
The abolished rewarding effect of methylphenidate in dopamine transporter knockout mice, a model for attention deficit/hyperactivity disorder Soichiro Ide, Jennifer Hua, Kazutaka Ikeda, Sarah Nagasawa, Yukio Takamatsu, Taishi-Clark Takeda Tokyo Metropolitan Institute of Medical Science, Japan Abstract Objectives: Attention deficit/hyperactivity disorder (AD/HD) is a heterogeneous neurobiological disorder characterized by inattention, impulsivity and hyperactivity. Although methylphenidate (MPH) has been used as a medication for AD/HD for many years, it is not well known whether exposure to MPH causes drug dependence. Dopamine transporter knockout (DAT-KO) mice are an AD/HD animal model, developed on the postulated role of DA, especially DAT. In the present study, we investigated rewarding effects of MPH by intracranial self-stimulation (ICSS) procedures using DAT-KO mice. Methods: DAT-KO and wild-type (C57BL/6J) mice (20-25 week old) were used. For the ICSS procedures, mice were trained to nose-poke to receive direct stimulations via an electrode placed in the lateral hypothalamus area. After acquisition of the behavior, either response-rate (progressive ratio) or frequency-rate (fixed ratio) procedures were investigated. Results: In response-rate procedures, DAT-KO mice showed an increased response-rate compared with wild-type mice. Treatment of 5 and 10 mg/kg MPH increased the response-rate in wild-type mice to the same level of that in naive DAT-KO mice. Meanwhile, MPH at the same doses did not affect DAT-KO mouse behaviors. Next, we further investigated effects of high-dose of MPH (60 mg/kg) in frequency-rate procedures. High-dose MPH caused immense decrement in responses at middle to higher frequency ranges (80-160 Hz) in wild-type mice. Further, highdose MPH also caused decrement in responses at higher frequency ranges (140-160 Hz) in DAT-KO mice.
Conclusion:
The results suggest that low-dose MPH causes changes in wild-type mice reward system to increase responserate to the same level as naive DAT-KO mice via DAT inhibition. Meanwhile, high-dose MPH could decrease ICSS behaviors via not only DAT inhibition but also by other mechanisms. Although the role of DAT in AD/HD is still controversial, it might be thought there is less risk of drug dependence to occur in AD/HD patients treated with MPH.
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17alfa-estradiol prevents gamma-aminobutyric signaling dysfunction induced by repeated stress in the hippocampus associated with behavioral abnormalities via G-protein-coupled estrogen receptor in ovariectomized mice Takao Tsukahara, Haruki Iwai, Masaaki Masuhara, Tomoaki Sato Kagoshima University, Japan Abstract In our previous study, we reported that repeated stress (RS) of forced gastric insertion in ovariectomized (OVX) mice induced less attention, impaired cognition associated with GABAergic functional deficit via the expression alterations of K + -Cl -cotransporter 2 (KCC2) and Na
co-transporter 1 (NKCC1) in the hippocampus. In this study, we aimed to investigate the effect of 17alfa-estradiol (alfaE2) as an anti-psychotic medicine and the involvement of G-protein-coupled estrogen receptor (GPR30) using immunohistochemical and behavioral analysis. 8-week-old C57/BL6J mice were OVX and/or RS were conducted for 21 days followed by several behavior tests. We found that GPR30 were overexpressed in the hippocampus of RS-OVX mice. Therefore, to prevent the overexpression of GPR30, we administered alfaE2 and G1, a GPR30 agonist, in RS-OVX mice. The administration prevented all the behavioral abnormalities and the expression alteration of KCC2, NKCC1 and GPR30. Additionaly, the efficacy of alfaE2 was completely diminished by co-administration of G15, an antagonist of GPR30. Subsequently, we evaluated the expressions of phosphorylated STE20-related
